AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|May 28, 2009
GSK to donate 50 million pandemic vaccines
21 May 2009
Advertisement
GlaxoSmithKline (GSK) has offered to donate 50 million doses of a pandemic vaccine to the World Health Organisation in the event of a global flu outbreak.
The offer was made during a meeting between UN officials, vaccine makers and othre health experts to discuss how to provide vaccines to poor countries if the swine flu outbreak goes global.
No pandemic vaccine exists yet, byt pharma companies claim they can begin production immediately once they get the vaccine's key ingredient, a 'seed stock' based on the virus. That is being developed by the Unites States's Centers for Disease Prevention and Control and should be available by mid-July.
GSK has already signed agreements with various countries to provide them with pandemic vaccine as soon as it becomes available. These include the UK, Belgium and Finland.
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
4
The Battle to Own the GLP-1 Patient Journey
5